

## Supplementary Information

# Intravitreal Dexamethasone Implant for Macular Oedema following vitrectomy for Epiretinal membrane and Retinal Detachment: A Systematic Review and Meta-analysis

Guglielmo Parisi<sup>1</sup>, Matteo Fallico<sup>2</sup>, Teresio Avitabile<sup>2</sup>, Antonio Longo<sup>2</sup>, Elina Ortisi<sup>2</sup>, Andrea Russo<sup>2</sup>, Francesco Petrillo<sup>2</sup>, Andrea Maugeri<sup>3</sup>, Martina Barchitta<sup>3</sup>, Vincenza Bonfiglio<sup>4</sup>, Claudio Furino<sup>5</sup>, Gilda Cennamo<sup>6</sup>, Paolo Caselgrandi<sup>1</sup>, Paola Marolo<sup>1</sup>, Luca Ventre<sup>1</sup> and Michele Reibaldi<sup>1</sup>

<sup>1</sup> Department of Surgical Sciences, Eye Clinic Section, University of Turin, 10122 Turin, Italy;

<sup>2</sup> Department of Ophthalmology, University of Catania, 95100, Catania, Italy;

<sup>3</sup> Department of Medical and Surgical Sciences and Advanced Technologies “GF Ingrassia”, University of Catania, Catania, Italy;

<sup>4</sup> Department of Experimental Biomedicine and Clinical Neuroscience, Ophthalmology Section, University of Palermo, 90127 Palermo, Italy;

<sup>5</sup> Department of Ophthalmology, University of Bari, Bari, Italy;

<sup>6</sup> Department of Public Health, University of Naples Federico II, Naples, Italy;

\* Dr Parisi and Dr Fallico contributed equally and should therefore be regarded as equivalent first authors.

### Corresponding author:

Matteo Fallico, MD

*Department of Ophthalmology, University of Catania, Via S. Sofia 76, 95100, Catania, Italy*

*email: [matteofallico@hotmail.com](mailto:matteofallico@hotmail.com)*

*phone number: +390957435711*

**Table S1: PRISMA 2009 Checklist.**

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			<b>1</b>
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			<b>2</b>
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			<b>4</b>
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
<b>METHODS</b>			<b>5-6</b>
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	-
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	6


Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
<b>RESULTS</b>			<b>7-9</b>
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	8
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8-9
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	8-9
<b>DISCUSSION</b>			<b>9-11</b>
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	9-10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	10-11
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	11
<b>FUNDING</b>			<b>12</b>
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	12

**Table S2:** Risk of bias of included studies according to the Methodological item for non-randomized studies (MINORS).

Author, year	clearly stated aim	consecutive patients	Prospective data collection	Endpoints appropriate to the aim of the study	Unbiased assessment of the study endpoint	Follow-up period appropriate to the aim of the study	Loss to follow up less than 5%	Prospective calculation of the study size	An adequate control group	Contemporary groups	Baseline equivalence of groups	Adequate statistical analyses	Total
Furino et al. 2014	2	2	0	2	2	2	2	0	NA	NA	NA	2	14/16
Hattenbach et al. 2017	2	0	0	2	2	1	2	0	NA	NA	NA	2	11/16
Chang et al.2018	2	0	0	2	2	2	2	0	2	2	2	2	18/24
Freissing et al. 2020	2	0	0	2	2	2	2	0	NA	NA	NA	2	12/16
Thanos et al.2017	2	2	0	2	2	1	2	0	NA	NA	NA	2	13/16
Chatziralli et al.2020	2	0	0	2	2	2	2	0	NA	NA	NA	2	12/16

Footnote: MINORS= Methodological item for non-randomized studies; 0= not reported; 1= reported, but inadequate; 2= reported and adequate; NA: not applicable.

**Figure S1:** Funnel plot for best corrected visual acuity change.



**Figure S2:** Funnel plot for central macular thickness change.

